Intellectual Property Strategies in the age of AI
In this recently published op-ed in CanadianSME, Conscience’s Chief Policy and Partnerships Officer, Richard Gold, and CEO, Peng Fu, call for biopharma SMEs to rethink their reliance on patents as they adopt AI. They argue that traditional patent-first IP strategies are increasingly misaligned with how AI actually works — because machine learning depends on broad […]
From risk to resilience: rethinking innovation in drug discovery
In a new op-ed for Drug Discovery World, Conscience CEO Peng Fu and Communications Lead Estrid Jakobsen argue that the biggest opportunities for progress in drug discovery lie not only in new technologies, but in reimagining how science itself is organized. They explore how open science, creative collaboration, and alternative incentive models can help the […]
Canadian SMEs Should Shift Perspectives on Patents to Enable Growth
In a recent op-ed published by Canadian SME Magazine, Conscience’s Chief Policy and Partnerships Officer Richard Gold makes the case for why Canadian science-based SMEs should consider open science not just as a philosophy—but as a practical strategy for growth. In an era where funding is uncertain and the costs of pursuing patents are often […]
AI drug development’s data problem
Richard Gold, Conscience’s Chief Policy and Partnerships Officer, has co-authored an editorial in Science with Robert Cook-Deegan calling for global coordination and public investment in high-quality, open datasets to enable AI-driven drug discovery. Drawing lessons from past successes like the Protein Data Bank and the Human Genome Project, the authors argue that the future of […]
As U.S. tariffs loom, Canada should use AI to fight back
Our Chief Policy and Partnerships Officer, Richard Gold, argues that Canada has a unique opportunity to become a global leader in AI-assisted drug discovery by leveraging its strong scientific expertise and biomedical data infrastructure. To reduce reliance on the U.S., Canada must invest in large, open datasets, streamline regulations, and foster collaboration between government, academia, and […]
In Vivo features Conscience among leading nonprofits addressing biopharma market failures
In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge Read the full article in In Vivo »
Canada Can Confront US Tariffs by Liberating Innovators
Our Chief Policy and Partnerships Officer, Richard Gold, argues that if Trump goes ahead with his tariffs, Canada should use intellectual property as a weapon against the threat to national economic security – a bold step that would allow Canada to exploit its wealth of academic knowledge to produce lower-cost medicines and ramp up AI-assisted […]
Forbes features top-scoring CACHE 2 team and highlights importance of participation from the Global South
How Can AI Help Discover ‘New’ Drugs Against COVID-19 In Brazil? Read the full article in Forbes »
Chemical & Engineering News features Conscience and top CACHE 2 participants
Open-source competition finds potential coronavirus drugs Read the full article on Chemical & Engineering News »
KBIA news features CACHE 2 participant Dmitri Kireev and Conscience CEO Ryan Merkley
MU researcher’s AI model advances coronavirus drug development Read the full article on KBIA News »
The Logic features top-scoring CACHE 2 team and Conscience CEO Ryan Merkley
The global contest, run by Toronto’s Conscience, hunting for the best AI tools to find new medicines Read the full article on The Logic »
The Globe & Mail talks with Conscience CEO Ryan Merkley about AI and drug discovery
In the quest for new medicines, developers seek to make AI their divining rod Read the full article on the theglobeandmail.com
